In contest prep the effective range is far lower than most people assume. J3 University coaches start clients around a quarter of a milligram per week, find that half a milligram goes a long way, and get most of what they want at or below 1 mg per week. Roughly 2 mg per week is the ceiling, and that is the outlier rather than the norm. The weekly total is usually split across two doses rather than given all at once, because appetite suppression hits hard for the first days after a dose and then tails off, and prep calls for a steadier effect than that. These are not clinical doses. Trials escalate to 8 to 12 mg per week, and everything below is written for a physique athlete whose prep is already doing most of the work.
GLP-1 stands for glucagon like peptide 1. It is an incretin hormone, released mainly through the gut in response to food. Its main effects are increased insulin secretion, which helps control blood glucose, and delayed gastric emptying, which is what makes you feel full. A GLP-1 agonist amplifies that. Food moves more slowly through the gut and you do not want to eat as much.
Tirzepatide added a second pathway, GIP, which is glucose dependent insulinotropic polypeptide. Combining the two means less GLP-1 agonism is needed for the same effect, so side effects come down slightly while the metabolic side improves.
Retatrutide adds a third. It is a triple agonist, and the piece it adds is the glucagon receptor. Glucagon receptor agonism increases hepatic glucose output and lipolysis, which can raise fasting glucose slightly and increase fat mobilisation. It may also modestly increase energy expenditure, though in practice the dominant effect is still appetite suppression.
Trials have shown roughly 15 to 20 percent body weight loss. That range comes from the highest dose arms, which used 8 to 12 mg per week. At a quarter of a milligram to 1 mg per week, which is the range this article is about, effects will be smaller and more variable. Do not read the trial headline as what a microdose delivers.
| Drug | Pathways | What the extra pathway adds |
|---|---|---|
| Semaglutide | GLP-1 | Appetite suppression and delayed gastric emptying |
| Tirzepatide | GLP-1 and GIP | Better metabolic effect at lower GLP-1 agonism |
| Retatrutide | GLP-1, GIP and glucagon | Hepatic glucose output, lipolysis, some energy expenditure |
One of the biggest misconceptions is that bodybuilders use retatrutide because they lack discipline or want an easier prep. That is usually not why experienced competitors reach for it.
Contest prep is not won because someone can tolerate the most hunger. It is won by creating enough fat loss while maintaining muscle, training performance, and recovery. Hunger is simply one variable that can limit execution. Retatrutide primarily helps by reducing the amount that hunger dictates your decisions. Instead of constantly thinking about food or fighting cravings, athletes can focus on training, recovery, posing, and adhering to the plan.
Beyond appetite suppression, retatrutide appears to modestly increase energy expenditure through glucagon receptor agonism. In practice this often means athletes can maintain fat loss while eating slightly more food than they otherwise would. Rather than continually removing carbohydrates throughout prep, some competitors can keep calories higher while achieving the same rate of loss. Worth separating two things that sound alike here. Retatrutide can let you hold calories higher for a given rate of loss, while at the same time making large volumes of food physically harder to get down because gastric emptying is slowed. The first is the benefit. The second is the cost, and it is why the back end of prep needs care.
That has downstream benefits. More food generally means better training performance, better pumps, improved recovery, better sleep, greater muscle retention, and less fatigue.
Ultimately the goal is not simply to eat less. The goal is to maintain as much food intake as possible while still producing the desired rate of fat loss. Retatrutide is one tool that may help accomplish that.
One of the biggest mistakes people make is assuming bodybuilding doses should resemble obesity treatment doses. They should not.
Clinical trials are treating individuals whose primary objective is maximising total weight loss. Contest prep has an entirely different objective. Bodybuilders are already creating an enormous energy deficit through calorie restriction, structured meal timing, high daily activity, cardio, resistance training, stimulants, thyroid medication where appropriate, and anabolic support.
Retatrutide is not replacing those strategies. It is being layered on top of them. Because the rest of prep is already doing so much of the work, relatively tiny doses often provide all the additional benefit that is needed.
The goal is not maximal appetite suppression. The goal is finding the minimum effective dose that improves adherence without compromising training performance or peak week.
The starting point is low. A quarter of a milligram per week is a normal place to begin, half a milligram covers a lot of people, and 1 mg per week is enough to get most of the available benefit without going further. There are outliers who end up in the 2 mg range, and that does a lot, but it is the rare case in prep rather than the target.
The weekly amount is usually split into two doses. Retatrutide has a long half life, but that does not mean it should be dosed purely off the half life. Dose it once and you get hard appetite suppression for the first few days that then tails off. Prep wants something more sustained than that, so spreading the dose out is the more useful pattern.
Escalation should be slow. Trials move in 4 week steps, and holding roughly 4 weeks at a dose before increasing is a reasonable rule outside them too. A conservative pattern is a quarter to half a milligram per week for weeks 1 to 4, then half a milligram to 1 mg per week for weeks 5 to 8, and only if weight loss is under half a percent per week with training and GI symptoms stable.
One note on language. The word microdosing gets used loosely here. The more useful meaning is dosing low relative to what the clinical studies used, which is what these numbers are.
| Weekly dose | Where it fits |
|---|---|
| A quarter of a milligram | A normal starting point |
| Half a milligram | Enough for a lot of athletes |
| 1 mg | Most of the benefit, without going further |
| 2 mg | The practical ceiling, and an outlier rather than a norm |
As the dose increases, appetite suppression becomes stronger but so do the downsides. The ability to consume adequate protein and carbohydrates decreases. Training performance starts falling. Recovery suffers. Sleep often worsens. Resting heart rate frequently increases.
Eventually the athlete is not limited by body fat anymore. They are limited by under fueling.
The objective is not to remove all hunger. A small amount of hunger during contest prep is completely normal. The objective is simply to reduce hunger enough that it no longer interferes with executing the plan. For most physique athletes that point occurs far below the doses used in obesity medicine.
For a sense of how far the misunderstanding goes: on the J3 University podcast, a coach describes a consult where a maximum of one or two milligrams was suggested, meaning per week, and the person had been reading about others taking one to three milligrams per day.
Most discussions focus on nausea and vomiting. Those certainly occur. But bodybuilders often notice different problems first, and they are the ones that cost you on stage.
Rather than increasing the dose on a schedule, adjustments should be driven by outcomes. Track weekly body weight, training volume, resting heart rate, and a simple GI symptom score. If you are on diuretics, check electrolytes every 4 weeks, and check kidney function if GI issues appear.
Hold or reduce the dose if weight loss exceeds 1 to 1.5 percent per week, if training volume drops more than 10 percent, or if GI symptoms persist.
The questions to keep asking are simple. Is the current rate of fat loss appropriate? Is training performance holding steady? Am I still completing all meals? Has resting heart rate increased substantially? Is recovery declining? Are GI symptoms starting to interfere with daily life?
If those variables are trending the wrong way, increasing the dose is usually the wrong answer. The minimum effective dose is almost always the best dose.
This is the part that decides whether the drug quietly ruins your peak. Retatrutide has roughly a six day half life, and clearing a compound takes about five half lives. That is a month before you are genuinely at zero.
So the taper starts earlier than people expect. Four to six weeks out is a reasonable point to begin bringing the dose down, aiming to be at or near zero by peak week so you have the best chance of filling back up. Full removal is not always necessary, but getting back to a low baseline is.
One coach on the show starts titrating around six to seven weeks out and removes fully at three to four weeks for athletes who are continuing to prep, on the basis that peak week data collected around ten days out is what guides the peak, and it needs to be clean. Where an athlete struggles with hunger management, titrating gradually all the way through to peak week is the alternative.
The reason to care is measurable. Delayed gastric emptying changes both how food is absorbed and how electrolytes balance, which makes the peak response inconsistent and hard to predict. That gets worse with larger athletes.
| Weeks out | What is happening |
|---|---|
| 6 to 7 weeks | Begin titrating the dose down |
| 4 to 6 weeks | The latest sensible point to start the taper |
| 3 to 4 weeks | Full removal, for athletes who manage hunger well |
| Peak week | At or near zero so you can fill back up and read the peak |
The concern usually raised is whether glucagon receptor agonism causes muscle loss directly. Current evidence does not suggest that is the primary mechanism.
When lean mass is lost during GLP-1 therapy it is largely because people are losing weight extremely quickly, consuming less protein, and not resistance training. Bodybuilders are in a completely different situation. They are resistance training multiple days per week. Protein intake is intentionally high. Most are also using anabolic support.
If weight loss is controlled appropriately and training quality remains high, significant muscle loss should not be expected simply because retatrutide is being used. The main risk to lean mass is the rate of energy deficit, not direct muscle catabolism.
The greater threat to muscle retention is allowing appetite suppression to become so severe that food intake and training performance begin deteriorating. That is a dosing problem, and it is the argument for the low doses above rather than against using the drug at all.
Post show can be harder to manage than prep. Appetite control is more difficult once the first genuinely enjoyable food arrives, and retatrutide is unusual in that it does not only suppress appetite, it changes the neurochemical signalling around cravings. Not completely. Athletes still report not being hungry while still wanting the food.
Coaches differ here. One reports using much the same dose range as in prep, another finds post show needs are usually lower. A typical pattern is to start the weekend of the show, titrate up as needed, then bring it back down as food goes up. The mistake is doing the opposite, adding more each time hunger appears, which ends with a skewed appetite and a bloated athlete.
One coach on the show reports not going above 1 mg per week in these cases, with half a milligram often accomplishing the goal. There is also a hazard in coming off a high dose abruptly at the end of dieting: the drug has been driving a large part of the insulin response, and without it you can end up insulin sensitive but in a low insulin secretion environment. Food has to come back up slowly and meal timing has to be paced. That is not a good environment for building tissue, which is another argument for keeping doses low from the start.
There is a bigger point underneath this. Used as a permanent substitute, the drug removes the need to learn hunger signalling, meal timing and food selection. Used as training wheels it can build a better relationship with post show eating, so that the following post show goes better. The goal is to get to the point of not needing it.
The offseason is where the drug is most often misapplied, and the reason is that people are drawn to the secondary benefits. Improved lipid profiles, better A1C readings, lower inflammation. Those are real and attractive, particularly for someone running growth hormone and a lot of food.
But the primary action of the drug directly opposes what an offseason is for. Something that slows gastric emptying is not the tool you want when you are trying to drive a lot of food in.
There is a first hand account of this on the show. A half milligram spread through the week seemed fine for four weeks. Moving to 1 mg brought poor sleep, a resting heart rate around 15 beats per minute above baseline, and a pounding heart at night that made sleep difficult. Recovery suffered badly despite plenty of other compounds present, and training only took off again once the drug had cleared. That was at 1 mg.
The narrow exception is an athlete who does not need much food in the offseason, has a family history of diabetes, wants to grow while using growth hormone, and whose A1C and lipid panel degrade quickly. When high food intake is not the objective, a low dose can fit. That is a specific profile, not a general recommendation.
The contraindications get discussed far less than the dosing, which is the wrong way round. Retatrutide is not approved, so the class warnings below come from the approved GLP-1 drugs and apply here by analogy rather than from a label of its own.
Some things are not dose adjustments. If any of the following happen, stop and get medical attention rather than titrating.
Retatrutide is a tool and not a first line solution. Most physique athletes do not need it, and set up wrong it can make a bodybuilding outcome worse rather than better. Work through this first.
This question comes up almost every time GLP-1 medications are discussed. Some people view using appetite modifying drugs as taking the easy way out. But bodybuilding has always been about using tools strategically. Cardio is a tool. PEDs are tools. Caffeine is a tool. Insulin is a tool. Growth hormone is a tool. Retatrutide is no different.
The drug does not make someone train harder, recover better, pose better, or consistently follow a nutrition plan. It simply removes one limiting factor, which is hunger. An athlete still has to execute every aspect of contest prep. At a dose that is actually appropriate, being able to keep food higher while maintaining fat loss often allows athletes to train harder and preserve more muscle than simply starving themselves. Push the dose up and that reverses, which is the point of the section above on why higher doses become counterproductive.
The goal is not to eliminate discipline. The goal is to make discipline easier to execute consistently over 20 to 30 weeks.
Lower than most expect. A quarter of a milligram per week is a normal starting point, half a milligram goes a long way, and 1 mg per week captures most of the benefit. Roughly 2 mg per week is the practical ceiling and an outlier rather than a norm. Clinical trials escalate to 8 to 12 mg per week, which is a different objective entirely.
Splitting the weekly amount across two doses is the more useful pattern in prep. A single dose produces hard appetite suppression for the first days that then tails off, and prep calls for a steadier effect.
Slowly. Trials escalate in 4 week steps, and holding about 4 weeks at a dose before increasing is sensible outside them too. Only increase if weight loss is under half a percent per week with training and GI symptoms stable. Hold or reduce if weight loss exceeds 1 to 1.5 percent per week or training volume drops more than 10 percent.
The half life is roughly six days, and clearing a compound takes about five half lives, so a full month is the realistic figure. That is why the taper needs to start four to six weeks out from a show.
Current evidence does not suggest the glucagon receptor causes muscle loss directly. Lean mass loss during GLP-1 therapy is largely driven by very fast weight loss, lower protein intake, and no resistance training. Keep the rate of loss controlled, protein high and training quality up, and significant muscle loss should not be expected.
Semaglutide acts on GLP-1. Tirzepatide adds GIP as a dual agonist. Retatrutide is a triple agonist that also hits the glucagon receptor, which increases hepatic glucose output and lipolysis and may modestly raise energy expenditure, though appetite suppression is still the dominant effect.
For most people no. Its primary action slows gastric emptying, which works directly against driving food in to grow. The narrow exception is an athlete who does not need much food, has a family predisposition to diabetes, and whose A1C and lipids degrade quickly.
J3 University walks through offseason, contest prep and peak week the same way this article does. Assess the tool, understand the mechanism, then decide whether it fits the athlete in front of you.
Explore J3 University
John Jewett is an IFBB Professional bodybuilder and physique coach, and the founder of J3 University. He has spent his career competing at the professional level while coaching competitors and everyday lifters through the same training, nutrition, and recovery principles he uses himself.
J3 University exists to make that process teachable. Every course is built on the reasoning behind the method, not just the method, so you can make better decisions about your own physique long after the program ends. The article above is drawn directly from the J3U course curriculum.
